Clinical Trial Update: Sequential Combo Immuno and Target Therapy (SECOMBIT) Study [Phase 2]

View source ↗

Summary

The SECOMBIT Phase 2 trial in metastatic melanoma has completed, evaluating sequential immunotherapy and targeted therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Fondazione Melanoma Onlus | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED